New Standard Of Care Secures EU OK For Neuroblastoma Drug
Changes in the EU in the standard of care for high-risk neuroblastoma has resulted in EUSA Pharma’s monoclonal antibody being approved by the European Commission under exceptional circumstances.
You may also be interested in...
The Scottish Medicines Consortium has recommended EUSA’s ultra-orphan neuroblastoma treatment Qarziba.
The European Medicines Agency has asked the European Commission to clarify whether generics of drugs authorized under exceptional circumstances should be subject to the same obligations as the reference product.